rs1554035308
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_000521.4(HEXB):c.512-1G>T variant causes a splice acceptor, intron change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000521.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HEXB | NM_000521.4 | c.512-1G>T | splice_acceptor_variant, intron_variant | Intron 3 of 13 | ENST00000261416.12 | NP_000512.2 | ||
HEXB | NM_001292004.2 | c.-164-1G>T | splice_acceptor_variant, intron_variant | Intron 3 of 13 | NP_001278933.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HEXB | ENST00000261416.12 | c.512-1G>T | splice_acceptor_variant, intron_variant | Intron 3 of 13 | 1 | NM_000521.4 | ENSP00000261416.7 | |||
HEXB | ENST00000511181.5 | c.-164-1G>T | splice_acceptor_variant, intron_variant | Intron 3 of 13 | 1 | ENSP00000426285.1 | ||||
HEXB | ENST00000510820.1 | n.231-1G>T | splice_acceptor_variant, intron_variant | Intron 1 of 3 | 3 | |||||
HEXB | ENST00000513079.5 | n.577-1G>T | splice_acceptor_variant, intron_variant | Intron 3 of 5 | 2 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 20
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Sandhoff disease Pathogenic:2
Variant summary: HEXB c.512-1G>T is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Three predict the variant abolishes a canonical 3' splicing acceptor site. These three tools also predict the variant creates or strengthens a cryptic 3' acceptor site 6 nucleotides downstream of the canonical site. At least one publication reports experimental evidence that this variant affects mRNA splicing, finding that a patient with the variant expresses transcripts lacking the first 6 nucleotides of exon 4, which is predicted to result in an in-frame deletion of the G171 and L172 residues (Zampieri_2008), located in the Beta-hexosaminidase, eukaryotic type, N-terminal domain (IPR029019) of the encoded protein. The variant was absent in 247230 control chromosomes (gnomAD). c.512-1G>T has been reported in the literature in an individual affected with Sandhoff Disease (Zampieri_2008). This patient was reported as compound heterozygous with another variant (c.299G>T) predicted to have a splicing impact, and RT-PCR and sequencing analysis did not find a transcript associated with this allele, indicating it produces an unstable transcript. These data suggest that c.512-1G>T is likely associated with disease. The following publication has been ascertained in the context of this evaluation (PMID: 18758829). One submitter has cited a clinical-significance assessment for this variant to ClinVar after 2014 and has classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at